血管紧张素ⅡⅠ型受体在人肝细胞癌中的表达及意义

Expression and Significance of Angiotensin Ⅱ TypeⅠ Receptor in Human Hepatocellular Carcinoma

目的:探讨血管紧张素ⅡⅠ型受体在人肝细胞癌中的表达情况及与肝癌病理学特征的关系。方法:运用免疫组织化学方法分析行手术切除的27例肝癌及癌旁组织以及9例正常肝组织的血管紧张素ⅡⅠ型受体的表达情况。结果:27例肝细胞癌有25例血管紧张素ⅡⅠ型受体阳性(92.6%),癌旁组织有 5 例阳性(18.5%),并且血管紧张素ⅡⅠ型受体阳性积分高低与肝癌的病理分期和组织学分级之间存在显著性差异(P<0.01)。而正常肝组织标本血管紧张素ⅡⅠ型受体均阴性。结论:血管紧张素ⅡⅠ型受体在肝癌的表达升高,是反映肝癌恶性程度的一个重要指标,可能是肝癌治疗的一个有用的靶分子。

Objective: To explore the expression of angiotensin Ⅱ type Ⅰ (AT1) receptor in human hepatocellular carcinoma and its relation to the tumor biological characteristics. Methods: Use immunohistochemical method to analyze the expression of AT1 receptor of hepatocellular carcimoma tissue and para-carcinoma tissue in 27 patients from January 2003 to December 2003 and 9 cases of normal hepatic tissues. Results: AT1 was expressed in 25 of 27(92.6%) cases of human hepatocellar carcinoma and in 5 of the 27(18.5%) cases of para-carcinomas. There were significant differences in levels of AT1 receptor positive grade among different pathological stages or histological grades (P<0.01). And the expression of AT1 receptor in normal hepatic tissues was negative. Conclusion: AT1 is expressed in the most hepatocellular carcinoma, and is up-regulated especially in the advanced pathological stage and poor differentiated tissues. Inhibition of AT1 is a possible useful therapeutic strategy for primary hepatocellular carcinoma.